Affibody AB:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Affibody AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3028
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Affibody AB (Affibody) is a biotech company that discovers and develops next generation biopharmaceuticals and related drugs. The company discovers and develops drugs based on its proprietary technology platforms such as Albumod and Affibody molecules. Its Affibody molecules are a class of antibody mimetics that surpass monoclonal antibodies and antibody fragments. Affibody’s Albumod technology is designed to enhance the efficacy of biopharmaceuticals. The company also provides pipeline products for inflammation and autoimmune disorders, cancer, and other diagnostics. It offers its products and services to patients suffering with autoimmune diseases, liver diseases, and psoriasis, among others. Affibody is headquartered in Stockholm, Sweden.

Affibody AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Affibody AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Affibody AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Affibody AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Affibody AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Affibody AB, Medical Devices Deals, 2012 to YTD 2018 9
Affibody AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Affibody AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Nordic Nanovector Enters into Co-Development Agreement with Affibody 11
Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 12
Affibody Enters Into Co-Development Agreement With Creative Antibiotics 13
Licensing Agreements 14
Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 14
Affibody Enters into Licensing Agreement with Biotest 15
Affibody Enters Into Licensing Agreement With Daiichi Sankyo For Albumod 16
AbClon Enters into Licensing Agreement with Affibody 17
Affibody Enters into Licensing Agreement with Daewoong Pharma for Albumod 18
Affibody AB – Key Competitors 19
Affibody AB – Key Employees 20
Affibody AB – Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Affibody AB, Pharmaceuticals & Healthcare, Key Facts 2
Affibody AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Affibody AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Affibody AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Affibody AB, Deals By Therapy Area, 2012 to YTD 2018 8
Affibody AB, Medical Devices Deals, 2012 to YTD 2018 9
Affibody AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nordic Nanovector Enters into Co-Development Agreement with Affibody 11
Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 12
Affibody Enters Into Co-Development Agreement With Creative Antibiotics 13
Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 14
Affibody Enters into Licensing Agreement with Biotest 15
Affibody Enters Into Licensing Agreement With Daiichi Sankyo For Albumod 16
AbClon Enters into Licensing Agreement with Affibody 17
Affibody Enters into Licensing Agreement with Daewoong Pharma for Albumod 18
Affibody AB, Key Competitors 19
Affibody AB, Key Employees 20

List of Figures
Affibody AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Affibody AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Affibody AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Affibody AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Affibody AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Affibody AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Affibody AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Affibody AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Affibody AB, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Affibody AB:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fast Track Diagnostics Ltd.:医療機器:M&Aディール及び事業提携情報
    Summary Fast Track Diagnostics Ltd. (Fast Track) is engaged in designing, manufacturing and supplying of infectious disease detection kits. It offers Real Time PCR multiplexing kits in human and veterinary line platforms. The company’s products comprises of FTD Human Papillomavirus (HPV) high risk k …
  • Takeda Pharmaceutical Company Limited:企業のM&A・事業提携・投資動向
    Takeda Pharmaceutical Company Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Takeda Pharmaceutical Company Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • Shanghai SECCO Petrochemical Co Ltd:企業の戦略的SWOT分析
    Shanghai SECCO Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Ipsos SA (IPS):企業の財務・戦略的SWOT分析
    Ipsos SA (IPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Eleison Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Eleison Pharmaceuticals LLC (Eleison Pharmaceuticals) is a drug development company that acquires, develops, and commercializes clinical stage drug candidates for orphan cancers. The company’s pipeline products include glufosfamide and inhaled lipid-complexed cisplatin. Its glufosfamide is a …
  • New Zealand Post Limited:企業の戦略的SWOT分析
    New Zealand Post Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Wal-Mart Stores Inc:戦略・SWOT・企業財務分析
    Wal-Mart Stores Inc - Strategy, SWOT and Corporate Finance Report Summary Wal-Mart Stores Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Dr. Reddy’s Research and Development BV-医療機器分野:企業M&A・提携分析
    Summary Dr. Reddy’s Research and Development BV (Dr. Reddy’s Research and Development), a subsidiary of Dr. Reddy's Laboratories Ltd is a drug formulation and manufacturing service provider that develops and manufactures improved injectable pharmaceuticals. The company offers services such as formul …
  • National Dentex Corp:企業の戦略的SWOT分析
    National Dentex Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Guangdong Zhongsheng Pharmaceutical Co Ltd (002317):製薬・医療:M&Aディール及び事業提携情報
    Summary Guangdong Zhongsheng Pharmaceutical Co Ltd (Guangdong Zhongsheng Pharma) is a pharmaceutical company that develops, manufactures and supplies Chinese patent medicines, medicinal herbs and chemical medicines. The company offers its products in the form of tablets, capsules, pills, injections, …
  • Export Development Canada-エネルギー分野:企業M&A・提携分析
    Summary Export Development Canada (EDC) is an export credit agency that provides financial services. The agency supports and promotes Canada’s export trade by providing finance and insurance solutions to companies with export contracts. It provides guarantees to banks to provide their exporting cust …
  • Puget Sound Energy Inc:電力:M&Aディール及び事業提携情報
    Summary Puget Sound Energy Inc (PSE), a subsidiary of Puget Energy Inc, is a utility service provider. The company offers offers services such as energy and natural gas supply, start service, power outages, natural gas safety, business services, natural gas storage and excess generation of energy. I …
  • Specialist Investment Properties PLC:企業の戦略・SWOT・財務分析
    Specialist Investment Properties PLC - Strategy, SWOT and Corporate Finance Report Summary Specialist Investment Properties PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Greggs Plc:企業の戦略・SWOT・財務情報
    Greggs Plc - Strategy, SWOT and Corporate Finance Report Summary Greggs Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Bangkok Bank Public Co Ltd:企業の戦略・SWOT・財務分析
    Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Avanir Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Avanir Pharmaceuticals Inc (Avanir) a subsidiary of Otsuka America, Inc. is a biopharmaceutical company which focuses on developing medicines for patients suffering from central nervous system disorders. The company’s lead products include NUEDEXTA (AVP-923), a first-in-class dual N-methyl-D …
  • Fuji Electric Co Ltd (6504):企業の財務・戦略的SWOT分析
    Fuji Electric Co Ltd (6504) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Shinhan Bank:企業の戦略・SWOT・財務情報
    Shinhan Bank - Strategy, SWOT and Corporate Finance Report Summary Shinhan Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • JetBlue Airways Corp:戦略・SWOT・企業財務分析
    JetBlue Airways Corp - Strategy, SWOT and Corporate Finance Report Summary JetBlue Airways Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Profire Energy Inc (PFIE):企業の財務・戦略的SWOT分析
    Summary Profire Energy Inc (Profire Energy) is an oilfield technology company that undertakes design, development, and installation of combustion management technology and chemical injection solutions. The company offers products such as burner management systems and chemical management systems. Its …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆